Based on Sauer et al. 2023, DOI: 10.1159/000530056
Induction Therapy Protocol Groups are based on:
Lenalidomide: VRD/RVd, Bortezomib (Velcade®)/Lenalidomide (Revlimid®)/Dexamethasone with or without additional antibody
VCD / PAD: VCD, Bortezomib (Velcade®)/Cyclophosphamide/Dexamethasone; PAD, Bortezomib (Velcade®) / Doxorubicin / Dexamethasone
VAD: VAD, Vincristine / Doxorubicin / Dexamethasone
Other: Use of altered or multiple induction therapy protocols - detailed listings can be found in the referenced publication.
The VAD induction therapy protocol was administered before the approval of Plerixafor, which is why it cannot be reliably considered in the statistical analysis regarding the probability of Plerixafor administration.
The calculation of the individual percentage risk p is based on the formula:

with

z: the log-odds value.
β0: The intercept.
βi: The regression coefficients for the metrics considered.
xi: The selection of corresponding patient characteristics.
The calculation of the expected collection result E is based on the following formula:

C: CD34+ cell count per microliter (µl) on the day of collection.
Eeff: Factor for collection efficiency, set at 0.3.
W: Patient's body weight in kilograms.
V: Processed blood volume during the leukapheresis session in liters.
Based on Rosenbaum et al. 2012, DOI: 10.3109/14653249.2011.652733